Back to Search
ADAM BRUFSKY, MD
MD
Specialist
NPI: 1518939537IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
MD059093L(PA)
Education
UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE
Class of 1990
Research & Publications (20)
Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
PMID 19675448·Am J Clin Oncol·2010
6-review
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
PMID 19433387·Clin Breast Cancer·2009
4-observational
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.
PMID 18366957·Curr Oncol Rep·2008
6-review
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
PMID 18377343·Expert Opin Pharmacother·2008
6-review
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
PMID 18515735·Oncologist·2008
3-trial
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
PMID 18305064·Oncologist·2008
6-review
Practical guidance for the management of aromatase inhibitor-associated bone loss.
PMID 18448451·Ann Oncol·2008
8-other
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
PMID 18282367·Clin Breast Cancer·2007
6-review
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
PMID 17159193·J Clin Oncol·2007
4-observational
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
PMID 16730272·Semin Oncol·2006
6-review
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
PMID 16137436·Clin Breast Cancer·2005
8-other
Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer.
PMID 19436037·J Natl Cancer Inst·2009
8-other
Bevacizumab in breast cancer: the best is yet to come?
PMID 19476262·Oncology (Williston Park)·2009
8-other
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
PMID 19228746·Clin Cancer Res·2009
3-trial
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
PMID 19051009·Breast Cancer Res Treat·2009
3-trial
Challenges of illness in metastatic breast cancer: a low-income African American perspective.
PMID 19538796·Palliat Support Care·2009
8-other
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
PMID 18427147·J Clin Oncol·2008
2-rct
Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy.
PMID 18467311·Ann Oncol·2008
4-observational
RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.
PMID 18757267·Clin Breast Cancer·2008
8-other
Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
PMID 18769331·Am J Surg Pathol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 300 HALKET ST, SUITE 4628
PITTSBURGH, PA 15213 - Phone
- (412) 641-6500
Quick Facts
- NPI
- 1518939537
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile